AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

GLENMARK, FOREST LABORATORIES IN $190-MILLION LICENSING DEAL (to develop the PDE4 inhibitor GRC 3886, a compound developed by Glenmark Pharmaceuticals).

Asia Africa Intelligence Wire

| September 24, 2004 | COPYRIGHT 2003 Financial Times Ltd. (Hide copyright information)Copyright

(From India Business Insight)

Glenmark Pharmaceuticals and the $2-billion USA-based Forest Laboratories have entered into a collaboration agreement to develop the PDE4 inhibitor GRC 3886, which is a compound developed by Glenmark. The drug is in development for chronic obstructive pulmonary disorder (COPD) and asthma.

As per the accord, Forest will develop, …

Related articles from newspapers, magazines, journals, and more
Glenmark Pharmaceuticals and Forest Laboratories announce collaboration...
News wire article from: Asia Africa Intelligence Wire September 23, 2004 700+ words
PHARMA FIRMS ABUZZ OVER GLENMARK DEAL (Glenmark Pharmaceuticals strikes a...
News wire article from: Asia Africa Intelligence Wire October 11, 2004 700+ words
ACTIVE ABROAD (Glenmark enters into an agreement with Forest Laboratories for...
News wire article from: Asia Africa Intelligence Wire October 10, 2004 700+ words
GLENMARK'S ASTHMA DRUG IN HUMAN TRIALS (Forest Laboratories Inc has bought...
Magazine article from: India Business Insight April 28, 2006 700+ words
Phase II b trials for oglemilast in asthma initiated. ( Forest Laboratories...
Magazine article from: India Business Insight November 30, 2008 700+ words
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily